The IMPACT31 trial will enrol 90 high-risk liver cancer patients across the US and Asia-Pacific to evaluate GNOS-PV02 ...
Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal ...
New Phase II/III study will evaluate ivonescimab plus chemotherapy against existing immunotherapy-based treatments, building ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results